Risk Factors for Ciprofloxacin Resistance in Bloodstream Infections Due to Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae

Microbial Drug Resistance

Volumn 10, Issue 1, 2004, Pages 71-76

  Kang, Cheol In ^a   Kim, Sung Han ^a   Kim, Dong Min ^a   Park, Wan Beom ^a   Lee, Ki Deok ^a   Kim, Hong Bin ^a   Oh, Myoung Don ^a,b   Kim, Eui Chong ^a,b   Choe, Kang Won ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAMASE; CIPROFLOXACIN; METRONIDAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; BILIARY TRACT INFECTION; BLADDER CATHETERIZATION; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; HUMAN; HUMAN TISSUE; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; BETA-LACTAMASES; CASE-CONTROL STUDIES; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LOGISTIC MODELS; MALE; MIDDLE AGED; RISK FACTORS;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; INSERTION SEQUENCES; KLEBSIELLA; KLEBSIELLA PNEUMONIAE;

EID: 1942466457     PISSN: 10766294     EISSN: None     Source Type: Journal    
DOI: 10.1089/107662904323047835     Document Type: Article

References (25)

1. Burwen, D.R., S.N. Banerjee, and R.P. Gaynes. 1994. The National Nosocomial Infections Surveillance System. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. J. Infect. Dis. 170:1622-1625.
2. Bush, K. 2001. New β-lactamases in gram-negative bacteria: Diversity and impact on the selection of antimicrobial therapy. Clin. Infect. Dis. 32:1085-1089.
3. Carratala, J., A. Fernandez-Sevilla, F. Tubau, et al. 1995. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin. Infect. Dis. 20:557-560.
4. Cometta, A., T. Calandra, J. Bille, and M.P. Glauser. 1994. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N. Engl. J. Med. 330:1240-1241.
5. Corbella, X., A. Montero, M. Pujol, et al. 2000. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J. Clin. Microbiol. 38:4086-4095.
6. Eisenstein, B.I., and D.F. Zaleznik. 2000. Enterobacteriaceae. In G.L. Mandell, J.E. Bennett, and R. Dolin (eds.). Principles and practice of infectious diseases, 5th ed. Churchill Livingstone, Philadelphia, PA, pp. 2294-2310.
7. Ena, J., C. Amador, C. Martinez, and V. Ortiz. 1995. Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli. J. Urol. 153:117-120.
8. Garner, J.S., W.R. Jarvis, T.G. Emori, et al. 1988. CDC definitions for nosocomial infections. Am. J. Infect. Control 16:128-140.
9. Itokazu, G.S., J.P. Quinn, C. Bell-Dixon, et al. 1996. Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. Clin. Infect. Dis. 23:779-784.
10. Jorgensen, J.H., J.D. Turnidge, and J.A. Washington. 1999. Antibacterial susceptibility tests: dilution and disk diffusion methods. In P.R. Murray, E.J. Baron, M.A. Pfaller, et al. (eds.). Manual of clinical microbiology, 7th ed. American Society for Microbiology, Washington, DC.
11. Karas, J.A., D.G. Pillay, and D. Muckart. 1996. Treatment failure due to extended-spectrum β-lactamase [letter]. J. Antimicrob. Chemother. 37:203-204.
12. Kern, W.V., E. Andriof, M. Oethinger, P. Kern, J. Hacker, and R. Marre. 1994. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob. Agents Chemother. 38:681-687.
13. Knaus, W.A., E.A. Drapier, D.P. Wagner, et al. 1985. APACHE II: a severity of disease classification system. Crit. Care. Med. 13:818-829.
14. Lautenbach, E., N.O. Fishman, W.B. Bilker, et al. 2002. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch. Intern. Med. 162:2469-2477.
15. Lautenbach, E., B.L. Strom, W.B. Bilker, et al. 2001. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin. Infect. Dis. 33:1288-1294.
16. Muder, R.R., C. Brennen, A.M. Goetz, M.M. Wagener, and J.D. Rihs. 1991. Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veteran's Affairs medical center. Antimicrob. Agents Chemother. 35:256-258.
17. National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial disk susceptibility tests. Approved standard. NCCLS document M100-S12. NCCLS, Wayne, PA.
18. Paterson, D.L. 2000. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin. Microbiol. Infect. 6:460-463.
19. Paterson, D.L., L. Mulazimoglu, J.M. Casellas, et al. 2000. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin. Infect. Dis. 30:473-478.
20. Pena, C., J.M. Albareda, R. Pallares, et al. 1995. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob. Agents Chemother. 39:520-524.
21. Richard, P., M.H. Delangle, D. Merrien, et al. 1994. Fluoroquinolone use and fluoroquinolone resistance: is there an association? Clin. Infect. Dis. 19:54-59.
22. Steward, C.D., K. Rasheed, S.K. Hubert, et al. 2001. Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the national committee for clinical laboratory standards extended spectrum β-lactamase detection methods. J. Clin. Microbiol. 39:2864-2872.
23. Thomason, K.S., and C.C. Sanders. 1992. Detection of extended-spectrum β-lactamases in members of the family Enterobacteriaceae: comparison of the double-disk and three-dimensional tests. Antimicrob. Agents Chemother. 36:1877-1882.
24. Troillet, N., M.H. Samore, and Y. Carmeli. 1997. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin. Infect. Dis. 25:1094-1098.
25. Tzelepi, E., P. Giakkoupi, D. Sofianou, et al. 2000. Detection of extended spectrum β-lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes. J. Clin. Microbiol. 38:542-546.